Curiosity, method and serendipity: the environment at NovImmune that fosters innovation and delivers

NovImmune is a cutting-edge, scientifically driven company with a pronounced dedication and commitment to immunology. The applied research team is strongly motivated to address the unmet medical needs of immunological-related disorders.
The disease-area focus is relevant as there are more than 80 autoimmune conditions that combined affect about 5% of the industrialized world's population, and for most of them there are no effective therapies available.

NovImmune’s strategy to discover new medicines is based on 5 pillars:

• Establish in-house predictive in vitro, in vivo and in silico models of human diseases to evaluate the medical potential of new mAbs
• Generate in-house lead candidates by mastering in-licensed technologies such as phage display libraries (CAT/Medimmune) and Medarex humanized transgenic mice
• Create a/o license-in new discovery assets to extend the technology platform
• Explore new targets and use validated targets to keep the balance in the portfolio risk profile
• Drive the discovery process by fostering a creative and motivating environment and making NovImmune the company of choice for excellent scientist